Health Intervention Sciences Group/Center for AIDS Intervention Research, Department of Psychiatry and Behavioral Medicine, Medical College of Wisconsin, 2071 N. Summit Avenue, Milwaukee, WI, 53202, USA.
Department of Psychology, Marquette University, Milwaukee, WI, USA.
Sci Rep. 2023 Mar 29;13(1):5116. doi: 10.1038/s41598-023-32014-8.
Intramuscular cabotegravir for long-acting injectable HIV pre-exposure prophylaxis (i.e., LAI-PrEP) was approved by the U.S. FDA in 2021. We sought to explore LAI-PrEP decision-making among a nationwide sample of young sexual minority men (YSMM) 17-24 years old. In 2020, HIV-negative/unknown YSMM (n = 41) who met CDC criteria for PrEP were recruited online to participate in synchronous online focus groups eliciting preferences and opinions about LAI-PrEP, as well as the impact of a potential self-administered option. Data were analyzed using inductive and deductive thematic analysis with constant comparison. Preferences and decision-making about LAI-PrEP varied widely among YSMM, with participants frequently comparing LAI-PrEP to oral PrEP regimens. We identified five key themes related to LAI-PrEP decision-making including concerns about adherence to PrEP dosing and clinic appointments, awareness and knowledge of PrEP safety and efficacy data, comfort with needles, minimizing PrEP stigma, and considerations of self-administration. YSMM acknowledged more PrEP options as beneficial to supporting uptake and persistence.
2021 年，美国食品药品监督管理局（FDA）批准了肌肉内 cabotegravir 用于长效注射型 HIV 暴露前预防（即 LAI-PrEP）。我们旨在探索全国范围内年轻性少数群体男性（YSMM）17-24 岁人群对 LAI-PrEP 的决策。2020 年，招募了符合预防用药物（PrEP）标准的 HIV 阴性/未知 YSMM（n=41），他们在线参加同步在线焦点小组，以了解他们对 LAI-PrEP 的偏好和意见，以及潜在的自我管理选项的影响。使用归纳和演绎主题分析以及恒定性比较对数据进行了分析。YSMM 对 LAI-PrEP 的偏好和决策差异很大，参与者经常将 LAI-PrEP 与口服 PrEP 方案进行比较。我们确定了与 LAI-PrEP 决策相关的五个关键主题，包括对 PrEP 剂量和就诊预约的依从性的担忧、对 PrEP 安全性和有效性数据的认识和了解、对针的舒适度、最小化 PrEP 污名化以及对自我管理的考虑。YSMM 认为更多的 PrEP 选择有利于支持接受和坚持。
J Acquir Immune Defic Syndr. 2025-4-15
J Acquir Immune Defic Syndr. 2024-12-15
N Engl J Med. 2021-8-12
Zotero 插件